Compare Johnson & Johnson (JNJ) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Prudential PLC — how do they compare? Johnson & Johnson trades at $260.48 (market cap $626.09B), while Prudential PLC trades at $27.63 (market cap $34.02B). The key difference: Johnson & Johnson is far larger — about 18.4× Prudential PLC's market cap, and Johnson & Johnson pays the higher dividend (2.06%). Which is the better fit depends on your goals.
| JNJ | PUK | |
|---|---|---|
Market Cap | $626.09B | $34.02B |
Volume | 6,156,228 | — |
Sector | Health | Financials |
52-Week High | $267.24 | $33.61 |
52-Week Low | $174.16 | $24.98 |
Enterprise Value | $654.37B | $35.46B |
Dividend Yield | 2.06% | 1.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Prudential PLC (PUK) trades at $27.495, down 2.57% today, with a bearish technical signal but strong fundamentals including a P/E of 8.92, net income margin of 14.52%, and robust cash flow from operations of $3.61B in 2024. Recent earnings beat expectations in Q4 2025, though Q4 2024 missed. The stock faces headwinds from China regulatory news impacting Asian operations, but analyst consensus remains 50% buy.
The outlook is mixed: attractive valuation and profitability support upside, but regulatory risks in China and bearish technicals pose near-term challenges. Investors should weigh strong cash generation and earnings beats against geopolitical exposures and market sentiment pressures for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
